Rapifen is indicated for:
- In adults, as an opioid analgesic supplement for use before and during anaesthesia.
- Short procedures and outpatient surgery.
- Procedures of medium and long duration when given as a bolus followed by supplemental doses or by continuous infusion.
At very high doses, Rapifen may be used in adults as an anaesthetic induction agent in ventilated patients.
Rapifen is indicated for use in neonates, infants, children and adolescents as:
- an opioid analgesic in association with a hypnotic to induce anaesthesia
- an opioid analgesic in association with general anaesthesia and for both short and long surgical procedures
For Rapifen Summary of Product Characteristics and Patient Information Leaflet, please click here.
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard
Adverse events should also be reported to Piramal Critical Care at https://piramalcriticalcare.com/complaints/